Aurobindo Pharma Management

Management criteria checks 3/4

Aurobindo Pharma's CEO is Kambam Reddy, appointed in Jun 2006, has a tenure of 17.92 years. total yearly compensation is ₹37.41M, comprised of 51.3% salary and 48.7% bonuses, including company stock and options. directly owns 5.58% of the company’s shares, worth ₹37.62B. The average tenure of the management team and the board of directors is 9.3 years and 5 years respectively.

Key information

Kambam Reddy

Chief executive officer

₹37.4m

Total compensation

CEO salary percentage	51.3%
CEO tenure	17.9yrs
CEO ownership	5.6%
Management average tenure	9.3yrs
Board average tenure	5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kambam Reddy's remuneration changed compared to Aurobindo Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹28b
Sep 30 2023	n/a	n/a	₹23b
Jun 30 2023	n/a	n/a	₹20b
Mar 31 2023	₹37m	₹19m	₹19b
Dec 31 2022	n/a	n/a	₹20b
Sep 30 2022	n/a	n/a	₹21b
Jun 30 2022	n/a	n/a	₹24b
Mar 31 2022	₹27m	₹14m	₹26b
Dec 31 2021	n/a	n/a	₹29b
Sep 30 2021	n/a	n/a	₹52b
Jun 30 2021	n/a	n/a	₹53b
Mar 31 2021	₹23m	₹20m	₹53b
Dec 31 2020	n/a	n/a	₹54b
Sep 30 2020	n/a	n/a	₹31b
Jun 30 2020	n/a	n/a	₹30b
Mar 31 2020	₹15m	₹13m	₹28b
Dec 31 2019	n/a	n/a	₹26b
Sep 30 2019	n/a	n/a	₹26b
Jun 30 2019	n/a	n/a	₹25b
Mar 31 2019	₹15m	₹13m	₹24b
Dec 31 2018	n/a	n/a	₹23b
Sep 30 2018	n/a	n/a	₹22b
Jun 30 2018	n/a	n/a	₹24b
Mar 31 2018	₹15m	₹13m	₹24b

Compensation vs Market: Kambam's total compensation ($USD448.70K) is about average for companies of similar size in the Indian market ($USD572.86K).

Compensation vs Earnings: Kambam's compensation has increased by more than 20% in the past year.

CEO

Kambam Reddy (65 yo)

17.9yrs

Tenure

₹37,406,887

Compensation

Mr. Kambam Nityananda Reddy has been Vice Chairman of Aurobindo Pharma Limited since June 1, 2012 and serves as a Whole Time Director of Aurobindo Pharma Limited since December 26, 1986 and serves as Manag...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kambam Reddy	Vice Chairman & MD	17.9yrs	₹37.41m	5.58% ₹ 37.6b
Mettu Madan Reddy	Whole-Time Director	no data	₹52.35m	0.00034% ₹ 2.3m
Santhanam Subramanian	Chief Financial Officer	9.8yrs	₹21.06m	no data
Sanjeev Dani	COO & Head of Formulations	8.8yrs	no data	no data
S. Kumar	President of Technical	no data	no data	no data
Arvind Bothra	Head of Investor Relations & Corporate Communications	no data	no data	no data
B. Reddy	Compliance Officer & Company Secretary	7.9yrs	₹4.76m	no data
G. Prasad	Senior Vice President of Global Finance & Operations	no data	no data	no data
Sudhir Singhi	Head of Global Finance Operations	no data	no data	no data
A. Rama Rao	President of Corporate QA	no data	no data	0.024% ₹ 164.7m
V. Handa	President of Chemical Research	no data	no data	no data
Gita Rao	Associate President of RAD- II	no data	₹9.14m	0% ₹ 0

9.3yrs

Average Tenure

62yo

Average Age

Experienced Management: 524804's management team is seasoned and experienced (9.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Kambam Reddy	Vice Chairman & MD	37.4yrs	₹37.41m	5.58% ₹ 37.6b
Mettu Madan Reddy	Whole-Time Director	17.7yrs	₹52.35m	0.00034% ₹ 2.3m
Makkapati Satakarni	President of Biologics	less than a year	no data	no data
Penaka Venkata Reddy	Non-Executive Director	37.4yrs	₹500.00k	3.07% ₹ 20.7b
Penaka Sarath Reddy	Non-Executive Director	16.7yrs	₹11.04m	no data
Santanu Mukherjee	Independent Director	1.3yrs	₹200.00k	no data
Deepali Pant Joshi	Director	no data	no data	no data
Savitha Mahajan	Additional Non-Executive Independent Director	6.4yrs	₹2.30m	no data
Venkat Chalasani	Independent Director of Apitoria Pharma Private Limited	1.1yrs	no data	no data
Mangalam Kumar	Independent Non-Executive Chairman	less than a year	no data	no data
Girish Vanvari	Non-Executive Independent Director	3.5yrs	₹2.70m	no data

5.0yrs

Average Tenure

63yo

Average Age

Experienced Board: 524804's board of directors are considered experienced (5 years average tenure).

Aurobindo Pharma Management

Management criteria checks 3/4

Key information

Recent management updates

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Insider recently sold ₹9.7m worth of stock

Recent updates

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Dividend reduced to ₹1.50

Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Price target increased by 7.2% to ₹1,071

Insider recently sold ₹9.7m worth of stock

Insider recently sold ₹1.6m worth of stock

New minor risk - Insider selling

Price target increased by 10% to ₹959

Upcoming dividend of ₹3.00 per share at 0.3% yield

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before December 4, 2023

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Associate President of RAD- II recently sold ₹1.6m worth of stock

Aurobindo Pharma Limited Announces Interim Dividend for the Financial Year 2022-23

Price target increased by 15% to ₹775

Aurobindo Pharma Limited Announces Resignation of M. Sivakumaran as Whole-Time Director and Director

Full year 2023 earnings: EPS misses analyst expectations

Aurobindo Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

Aurobindo Pharma Limited Receives USFDA Approval for Saxagliptin Tablets, 2.5 Mg and 5 Mg

Aurobindo Pharma Limited, Annual General Meeting, Aug 25, 2023

Aurobindo Pharma Limited Announces Completion of US Fda Inspection At Unit III At Bachupally Village, Medchal Malkajgiri District, Telangana

Aurobindo Pharma Limited Announces Classification of US FDA Inspection At Unit XIV, Anakapalli District, Andhra Pradesh

Price target increased by 9.0% to ₹643

Full year 2023 earnings: EPS misses analyst expectations

Insider recently sold ₹1.3m worth of stock

Insider recently bought ₹3.2m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before March 3, 2023

Aurobindo Pharma Limited Announces Completion Of US FDA Inspection At Unit IX - Reg

Price target decreased to ₹621

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹11m worth of stock

Insider recently sold ₹2.7m worth of stock

Aurobindo Pharma Limited (NSEI:AUROPHARMA) completed the acquisition of 34% stake in GLS Pharma Ltd from Suresh and Sunita Pathak.

First quarter 2023 earnings released: EPS: ₹8.88 (vs ₹13.14 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc. Announces Settlement with Aurobindo to Resolve AUSTEDO® (deutetrabenazine) Patent Dispute

Price target decreased to ₹734

Aurobindo Pharma Limited Announces Fourth Interim Dividend for the Financial Year 2021-22, Payable on or Before June 15, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Less than half of directors are independent

Aurobindo Pharma Limited (NSEI:AUROPHARMA) agreed to acquire Domestic formulation business of Veritaz Healthcare from Veritaz Healthcare Limited for INR 1710 million.

Aurobindo Pharma Limited (NSEI:AUROPHARMA) agreed to acquire Business and certain assets of Veritaz Healthcare Limited for 1710 million.

Blackstone Reportedly Closing in on Aurobindo's Injectables Business

Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio

Insider recently sold ₹2.4m worth of stock

Insider recently sold ₹2.4m worth of stock

Now 20% undervalued

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Aurobindo Reportedly in Advanced Talks with Global PE Funds

Several Firms Reportedly Sounded Off to Buy Stake in Injectable Business of Aurobindo Pharma

Insider recently sold ₹2.1m worth of stock

Second quarter 2022 earnings released: EPS ₹11.89 (vs ₹13.75 in 2Q 2021)

Insider recently sold ₹4.0m worth of stock

Insider recently sold ₹1.1m worth of stock

Upcoming dividend of ₹1.50 per share

Price target decreased to ₹1,009

Investor sentiment deteriorated over the past week